Printer Friendly

UCB Japan Obtains FDA Approval of Treatment Drug for Epilepsy Patients.

Tokyo, Japan, Aug 14, 2006 - (JCN) - UCB Japan, a leading global biopharmaceutical company has obtained the approval of Keppra - generic name levetiracetam - 500mg/5mL (100mg/mL) from the U.S. Food and Drug Administration (FDA) for use as an adjunctive therapy for treatment of partial-onset seizures in adults with epilepsy.

The 15- minute intravenous infusion of Keppra offers an alternative for patients who find oral administration difficult or temporarily not feasible. The drug is prescribed to adults and children four years of age and older with epilepsy.

Keppra has already been approved in March 2006 from the European Commission.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Aug 15, 2006
Words:109
Previous Article:NIAS and Sanger Institute Concludes Agreement on Pig Genome Research.
Next Article:Arosystem to Release 3DCG AMD Opteron CAD/CAM.


Related Articles
FDA Gives Salvage Therapy Testing a Push Forward.
An overview of the drug approval process. (FDA Overview).
Averting pain: epilepsy drug limits migraine attacks.
FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides.
Lawsuits fault off-label use of Neurontin in suicide cases.
Astellas Pharma Receives FDA Approval for Hyponatremia Drug VAPRISOL.
Pfizer Japan Obtains Manufacturing Approval of Gabapentin for Antiepileptic.
UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.
UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters